Animal Health Solutions

KBroVet®-CA1 (potassium bromide chewable tablets) For complete prescribing information, see full package insert. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling. Indication: for the control of seizures associated with idiopathic epilepsy in dogs. Warnings: Not for human use. Keep out of reach of children. Contact a physician in case of accidental ingestion by humans. KBroVet®-CA1 should not be used in animals with a history of hypersensitivity to bromide or any of the components of the tablets. Not for use in cats. Keep tablets in a secured location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. Precautions: The safe use of KBroVet-CA1 Chewable Tablets has not been evaluated in dogs that are intended for breeding, that are pregnant or lactating, or less than 6 months of age. Reproductive effects of potassium bromide (KBr) have been reported in other species. In dogs, ataxia, diarrhea, hematochezia, excessive salivation, shivering, skin lesions, stupor progressing to coma, and death have been reported with high doses. 1,2 Dogs receiving KBroVet-CA1 should be carefully monitored when changing diets, administering chloride-containing IV fluids, and administering concurrent medications. Careful monitoring is important in dogs that have a condition that may cause difficulty maintaining electrolyte balance. Animals with decreased renal function may be predisposed to bromide toxicosis. Some dogs may experience epileptic episodes that are unresponsive or refractory to KBr monotherapy and KBr alone may not be adequate treatment for every dog with idiopathic epilepsy. Adverse Reactions: In a retrospective field of study of 51 dogs diagnosed with idiopathic epilepsy and treated with KBr, the most common clinical abnormalities documented in the 60 day period after start of KBr therapy were increased appetite, weight gain, vomiting/regurgitation and sedation. Additional field reports of clinical abnormalities in dogs dosed with KBr for idiopathic epilepsy showed polyphagia, polyuria, polydipsia, weight gain, lethargy and decreased physical activity. Ataxia was the most common body-system (i.e. CNS) specific clinical finding. Adverse events associated with concurrent use of KBr with other antiepileptic drugs such as phenobarbital have been reported, including sedation, irritability, restlessness, depression, behavioral changes, ataxia, hind limb paresis, mydriasis, stupor, and coma. These neurologic signs were reported to be reversible. 1,3 Reasonable Expectation of Effectiveness: This drug is conditionally approved pending a full demonstration of effectiveness. In a dose determination retrospective study involving a total of 284 canine case records, the mean total oral dose was determined to be 46.6 (±21.9) mg/kg/day with a range of 24.5-68.3 mg/kg/day, describing the range to achieve serum bromide concentrations within 10% of the published therapeutic range for dogs with idiopathic epilepsy. In a pilot retrospective study spanning a 5.7 year period, involving the review of case records of 51 client-owned dogs contributed by 18 veterinarians, and comparing the 30 day period before initial treatment with KBr and the 30 day period of steady state KBr dosing, 27 cases were determined as valid for evaluation of effectiveness. The mean maintenance dose in those 27 cases was 37 mg/kg/day, with a mean duration of 286 days. Approximately 67% of those cases were dosed once daily and 33% were dosed twice daily. Based on seizure count results, 70% of the 27 cases were defined as "success" and 30% were defined as "failures." Based on seizure event day results, 67% were defined as "success" and 33% were defined as "failures." Seizure severity score decreased or did not change in 25 of the 27 cases evaluated for effectiveness. Overall, of the 27 dogs included in the effectiveness analysis, 67% were considered treatment successes and 33% were considered treatment failures. To obtain full product information please call 800-874-9764 or visit KBroVet.com. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-544. Pegasus Laboratories, Inc. Dosage and Administration: For use in dogs only. The total recommended daily dosage range for KBroVet Chewable Tablets is 25-68 mg/kg, dosed with or without food, and should be adjusted based on monitoring of clinical response of the individual patient. 4 Use of an initial loading dosage regimen may be considered on an individual patient basis, balancing the time required to achieve a therapeutic response while minimizing side effects. Storage: Store at 20-25°C (68-77°F). WARNINGS: NOT FOR USE IN HUMANS. KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN. 1. Baird-Heinz, H. E., Van Schoick, A. N. L., Pelsor, F. R., Ranivand, L., & Hungerford, L. L. (2012). A systematic review of the safety of potassium bromide in dogs. Journal of the American Veterinary Medical Association, 240(6), 705-715. 2. Nichols, E. S., Trepanier, L. A., & Linn, K. (1996). Bromide toxicosis secondary to renal insufficiency in an epileptic dog. Journal of the American Veterinary Medical Association, 208(2), 231-233. 3. Boothe, D. M., Dewey, C., & Carpenter, D. M. (2012). Comparison of phenobarbital with bromide as a first-choice antiepileptic drug for treatment of epilepsy in dogs. Journal of the American Veterinary Medical Association, 240(9), 1073-1083. 4. Podell, M., & Fenner, W. R. (1993). Bromide therapy in refractory canine idiopathic epilepsy. Journal of Veterinary Internal Medicine, 7(5), 318-327. Gain confidence in your anesthesia delivery with realistic simulation training 8 hours RACE CE (10+ hours with pre-learning courses) LEARNING OBJECTIVES: Identify and manage anesthetic complications in your patients. Recognize and respond to changes in blood pressure, CO₂ and cardiac arrhythmias, leading contributors to anesthetic emergencies. Increase confidence in operating and maintaining your anesthesia and monitoring equipment. Practice communicating effectively in surgical situations and managing stress for better outcomes. Level-set your clinical team on best practices in anesthetic case management. Join the learning experience: midmarkacademy.com Veterinarians and credentialed technicians who complete this session will earn 8 hours of CE credit (10+ hours with pre-learning courses).* At least one DVM should be a participant on training day. *This in-clinic training has been approved for 8 hours of continuing education credit, with 10+ hours of continuing education credit available when pre-learning courses are completed, in jurisdictions that recognize RACE approval. Price and availability vary for clinics located outside the continental United States. Midmark Academy Foundations in Veterinary Anesthesia and Simulation Workshop

• Cover